Intralymphatic histiocytosis in a patient with lung adenocarcinoma treated with pembrolizumab: a case report

Journal for Immunotherapy of Cancer
Teppei SuganoAkihiko Gemma

Abstract

Pembrolizumab, an anti-programmed cell death-1 protein monoclonal antibody, is effective for patients with advanced non-small-cell lung cancer. However, immune checkpoint inhibitors such as pembrolizumab induce various immune-related adverse events, involving the lung, liver, gastrointestinal, endocrine system, and skin. Intralymphatic histiocytosis (ILH) is a rare, chronic cutaneous disorder with a reactive inflammatory component, which often occurs in patients with rheumatoid arthritis. We present a 67-year-old man with lung adenocarcinoma who developed ILH associated with pembrolizumab treatment. He was treated with palliative thoracic radiotherapy for superior vena cava syndrome. Subsequently, he received four cycles of pembrolizumab. Approximately 2.5 months after the initiation of pembrolizumab, he developed erythema on the trunk of his body. Based on findings of skin biopsies, he was diagnosed with pembrolizumab-induced ILH. Moreover, the upregulation of tumor necrosis factor-α was observed during pembrolizumab therapy. This is the first report of ILH induced by pembrolizumab in a patient with lung adenocarcinoma.

References

Mar 1, 1994·Histopathology·J T O'GradyA al-Nafussi
May 1, 1953·The British Journal of Radiology·R H MOLE
Mar 26, 2009·The American Journal of Dermatopathology·Luis RequenaHeinz Kutzner
Jan 19, 2011·Archives of Dermatology·Masanobu SakaguchiChikako Nishigori
Jan 21, 2014·Journal of the American Academy of Dermatology·Farrah BakrAlistair Robson
Jul 30, 2015·JAMA Dermatology·Martina SanlorenzoSusana Ortiz-Urda
Sep 17, 2015·Journal of Cutaneous Pathology·Eleonora BarbaGiampiero Girolomoni
Jan 15, 2016·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·J M MichotO Lambotte
Jan 23, 2016·Journal of the American Academy of Dermatology·Shelley Ji Eun HwangPablo Fernandez-Penas
Sep 25, 2016·Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association·Shunichi YanaiTakayuki Matsumoto
Oct 11, 2016·The New England Journal of Medicine·Martin ReckUNKNOWN KEYNOTE-024 Investigators
Nov 20, 2016·Journal of Cutaneous Pathology·Jonathan L CurryVictor G Prieto
Jun 5, 2017·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Takeshi UenamiSoichiro Yokota
Sep 9, 2017·The New England Journal of Medicine·Scott J AntoniaUNKNOWN PACIFIC Investigators

❮ Previous
Next ❯

Citations

May 14, 2020·Journal of Cutaneous Pathology·Joshua F Goldsmith, Steven R Tahan
Aug 2, 2021·Journal of the American Academy of Dermatology·Henry T QuachAnna K Dewan

❮ Previous
Next ❯

Methods Mentioned

BETA
biopsy

Related Concepts

Related Feeds

Cancer Immunotherapy

Cancer immunotherapy is an important field of research that is looking at controlling cancer and tumor growth by activating the individuals own immune system. Recent studies have utilized chimeric antigen receptor t-cell therapy, immune checkpoint inhibitors and neoantigen vaccines. Discover the latest research on cancer immunotherapy here.

Related Papers

Lung Cancer : Journal of the International Association for the Study of Lung Cancer
Takeshi UenamiSoichiro Yokota
The American Journal of Dermatopathology
Kristine M CornejoPatrick OʼDonnell
Hepatology : Official Journal of the American Association for the Study of Liver Diseases
Kohei OgawaShuji Terai
© 2022 Meta ULC. All rights reserved